Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Juzentaihoto for fatigue in advanced gastric/esophageal/EGJ cancer receiving ICI-combined chemotherapy (DURGA 0)
jRCTs071250144Recruiting
- Sponsor
- Tsumura & Co.
- Start
- Mar 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of juzentaihoto in gastric cancer (GC), esophageal cancer and esophagogastric junction cancer, sponsored by Tsumura & Co. Primary endpoint: FACIT-F at 12 weeks. Started Mar 2026; status: recruiting.
02
Drugs
juzentaihoto
03
Conditions
gastric cancer (GC)esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on jRCTs071250144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071250144.